SEK 0.51
(-5.9%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 228 Thousand SEK | 100.67% |
2022 | -39.98 Million SEK | 0.25% |
2021 | - SEK | -447.35% |
2020 | -6.72 Million SEK | 4.49% |
2019 | -187.98 Thousand SEK | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q1 | -6.79 Million SEK | 0.0% |
2024 Q2 | -5.72 Million SEK | 15.74% |
2023 Q2 | -8.03 Million SEK | -59.83% |
2023 Q4 | -6.42 Million SEK | 14.77% |
2023 Q3 | -7.53 Million SEK | 6.23% |
2023 Q1 | -5.02 Million SEK | 22.61% |
2023 FY | - SEK | -2.29% |
2022 Q1 | -5.01 Million SEK | 49.19% |
2022 FY | - SEK | 0.25% |
2022 Q4 | -6.49 Million SEK | 55.23% |
2022 Q3 | -14.51 Million SEK | -82.28% |
2022 Q2 | -7.96 Million SEK | -58.69% |
2021 Q4 | -9.87 Million SEK | -50.02% |
2021 Q2 | -12.54 Million SEK | -51.04% |
2021 FY | - SEK | -447.35% |
2021 Q1 | -8.3 Million SEK | 0.0% |
2021 Q3 | -6.58 Million SEK | 47.52% |
2020 FY | - SEK | 4.49% |
2019 FY | - SEK | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Alligator Bioscience AB (publ) | -237.61 Million SEK | 100.096% |
Ziccum AB (publ) | -20.34 Million SEK | 101.121% |
Modus Therapeutics Holding AB (publ) | 2000.00 SEK | -11300.0% |
BioArctic AB (publ) | 275.38 Million SEK | 99.917% |
Sprint Bioscience AB (publ) | -2.08 Million SEK | 110.962% |
Mendus AB (publ) | -97.84 Million SEK | 100.233% |
Genovis AB (publ.) | 64.57 Million SEK | 99.647% |
Intervacc AB (publ) | -68.98 Million SEK | 100.331% |
QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | 101.698% |
Active Biotech AB (publ) | -43.88 Million SEK | 100.52% |
Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 99.274% |
Bio-Works Technologies AB (publ) | -54.8 Million SEK | 100.416% |
Aptahem AB (publ) | -10 Million SEK | 102.278% |
Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 100.072% |
Kancera AB (publ) | -61.88 Million SEK | 100.368% |
Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 98.026% |
Fluicell AB (publ) | -25.91 Million SEK | 100.88% |
Saniona AB (publ) | -69.69 Million SEK | 100.327% |
Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | 101.884% |
Biovica International AB (publ) | -119.5 Million SEK | 100.191% |
Spago Nanomedical AB (publ) | -42.22 Million SEK | 100.54% |
AcouSort AB (publ) | -16.7 Million SEK | 101.365% |
Xintela AB (publ) | -53.47 Million SEK | 100.426% |
Abliva AB (publ) | -93.6 Million SEK | 100.244% |
Egetis Therapeutics AB (publ) | -319.1 Million SEK | 100.071% |
Karolinska Development AB (publ) | -26.78 Million SEK | 100.851% |
OncoZenge AB (publ) | 7.26 Million SEK | 96.862% |
Amniotics AB (publ) | -27.14 Million SEK | 100.84% |
2cureX AB (publ) | -35.13 Million SEK | 100.649% |
CombiGene AB (publ) | -35.33 Million SEK | 100.645% |
Asarina Pharma AB (publ) | -14.21 Million SEK | 101.604% |
Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 100.062% |
Camurus AB (publ) | 562.54 Million SEK | 99.959% |
Corline Biomedical AB | -1.69 Million SEK | 113.483% |
IRLAB Therapeutics AB (publ) | -173.32 Million SEK | 100.132% |
Isofol Medical AB (publ) | -37.02 Million SEK | 100.616% |
I-Tech AB | 30.34 Million SEK | 99.249% |
Hansa Biopharma AB (publ) | -714.55 Million SEK | 100.032% |
Cyxone AB (publ) | -20.41 Million SEK | 101.117% |
ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | 100.223% |
Cantargia AB (publ) | -284.31 Million SEK | 100.08% |
NextCell Pharma AB | -40.98 Million SEK | 100.556% |
Xspray Pharma AB (publ) | -169.81 Million SEK | 100.134% |
Elicera Therapeutics AB (publ) | -17.08 Million SEK | 101.335% |
Nanologica AB (publ) | -62.11 Million SEK | 100.367% |
SynAct Pharma AB | -222.7 Million SEK | 100.102% |
Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | 100.52% |
Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 26.312% |
LIDDS AB (publ) | -39.67 Million SEK | 100.575% |
Lipum AB (publ) | -37.11 Million SEK | 100.614% |
BioInvent International AB (publ) | -312.7 Million SEK | 100.073% |
Alzinova AB (publ) | 41.99 Thousand SEK | -442.87% |
Oncopeptides AB (publ) | -231.62 Million SEK | 100.098% |
Pila Pharma AB (publ) | -8.81 Million SEK | 102.587% |
Guard Therapeutics International AB (publ) | -114.9 Million SEK | 100.198% |
Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | 101.165% |
Simris Alg AB (publ) | -22.36 Million SEK | 101.02% |
Diamyd Medical AB (publ) | -140.85 Million SEK | 100.162% |
Xbrane Biopharma AB (publ) | -282.03 Million SEK | 100.081% |
Ascelia Pharma AB (publ) | -108.55 Million SEK | 100.21% |
Diagonal Bio AB (publ) | -11.46 Million SEK | 101.988% |